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ABSTRACT
CATNAP (Compile, Analyze and Tally NAb Panels)
is a new web server at Los Alamos HIV Database,
created to respond to the newest advances in HIV
neutralizing antibody research. It is a comprehen-
sive platform focusing on neutralizing antibody po-
tencies in conjunction with viral sequences. CATNAP
integrates neutralization and sequence data from
published studies, and allows users to analyze that
data for each HIV Envelope protein sequence posi-
tion and each antibody. The tool has multiple data
retrieval and analysis options. As input, the user
can pick specific antibodies and viruses, choose a
panel from a published study, or supply their own
data. The output superimposes neutralization panel
data, virus epidemiological data, and viral protein se-
quence alignments on one page, and provides fur-
ther information and analyses. The user can high-
light alignment positions, or select antibody con-
tact residues and view position-specific information
from the HIV databases. The tool calculates tallies
of amino acids and N-linked glycosylation motifs,
counts of antibody-sensitive and -resistant viruses in
conjunction with each amino acid or N-glycosylation
motif, and performs Fisher’s exact test to detect po-
tential positive or negative amino acid associations
for the selected antibody. Website name: CATNAP
(Compile, Analyze and Tally NAb Panels). Website
address: http://hiv.lanl.gov/catnap.
INTRODUCTION
Despite more than 30 years of focused scientific efforts
worldwide, creating an effective HIV vaccine has proven
difficult. HIV is extraordinary variable (1) and designing a
vaccine able to stimulate immunological responses that will
broadly cross-react with circulating variants is a challenge.
Inducing neutralizing antibodies that can block viral infec-
tion of a target cell is considered essential for an effective
vaccine. Several breakthrough experimental techniques de-
veloped in recent years allowed highly efficient interroga-
tion of human memory B cells and plasma cells and conse-
quently the isolation of many broadly neutralizing antibod-
ies (bNAbs) (2). These bNAbs are able to neutralize mul-
tiple circulating HIV-1 strains, and large panels of pseudo-
typed viruses are used to assess the neutralization breadth
and potency of these antibodies (3–7).
Neutralization panel data is usually available in the sup-
plemental materials of the published studies and includes
IC50, and for some studies IC80, neutralization values (the
concentration atwhich infectivity is reduced by 50%or 80%,
respectively (7)) for multiple antibodies and hundreds of
viruses. Depending on the study, antibody structure and
antibody sequences may also be available. The accumula-
tion of these new monoclonal antibodies together with the
vast related neutralization panel information requires stor-
age, comparison and analysis tools. Several databases and
servers to organize and access this data have become avail-
able in recent years (8–10). The standalone program Anti-
bodyDatabase (8) provides an integrated platform for ex-
amining sequence, structure, and neutralization data in a
holistic way; however this tool is not a web server. The bN-
Aber database (9) collects neutralization scores and avail-
able antibody structures and sequences of the most impor-
tant bNAbs, and has very useful visualization and analysis
tools. The Neutralization-based Epitope Prediction (NEP)
server predicts antibody-specific epitopes at the residue level
based on neutralization panels of viral strains, using the
user’s data (10,11). These important web-based resources,
however, do not contain the viral sequence data, and so
do not readily enable the exploration of how HIV Enve-
lope (Env) sequence variation is correlated with the neu-
tralization sensitivity. The combination of published neu-
tralization scores, antibody sequences, and viral sequences
commonly used for the evaluation of neutralizing antibod-
ies, together with initial analysis of bNAb associations with
viral sequence mutations has first become available on the
web through our new tool CATNAP (Compile, Analyze
and Tally NAb Panels), available at the Los Alamos HIV
Database. In addition, many large Env panels are published
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without accession numbers, and with wide discrepancies
in sequence names used by different laboratories, making
subsequent comparisons between studies andmeta-analysis
difficult. Given that Los Alamos HIV Database project has
a mission of bringing together global HIV sequence and
immunology data, we worked with the primary investiga-
tors to systematically determine the exact viruses used for
neutralization studies in different laboratories. This has en-
abled an integrated view of HIV Envelope sequences, neu-
tralizing antibody IC50 and IC80 data, and descriptions of
HIV Env/antibody contact residues, collected from multi-
ple studies and put into the framework of our database tools
and web services. Links to Antibody/Env structures and
complete information of antibody sequence data are also
provided, and better visualization tools for this data are un-
der development.
In this report, we focus on CATNAP, a web-based portal
of neutralizing antibody IC50 and IC80 values in conjunc-
tionwith viral data, inspired by studies byWest et al. (8) and
Gnanakaran et al. (12). CATNAP allows users to superim-
pose neutralization results and virus sequences from pub-
lished sources and their own data, and perform initial analy-
sis to find potential neutralization antibody signatures. This
tool is a part of our larger neutralization antibody resources
page at the Los Alamos HIV Database, which includes sev-
eral other useful sources of information, such as a table
of best neutralizing antibodies, a list of external tools for
germline antibody reconstruction (13–18), an HIV genome
browser, and the neutralizing antibody contexts and fea-
tures database. The latter is compiled from multiple refer-
ences and contains coordinates of important neutralizing
antibody contact sites (3,4,19–28), mutations affecting neu-
tralization sensitivity (22,29), CD4 contacts (4,26) cytoplas-
mic tail interactions (30), and antibody sensitivity signature
predictions (8,10,11). CATNAP taps into the neutralizing
antibody contexts and features database and links to our
HIV Immunology and Sequence databases, allowing the
rich data collected in these databases to be directly incor-
porated into the analysis.
MATERIALS AND METHODS
The neutralization panel data (IC50 and IC80 values for
specific monoclonal antibodies and pseudotyped viruses)
were collected from 49 published neutralization studies,
mostly from tables in PDF format provided in the supple-
mental materials. The viral data was collected from Los
Alamos HIVDatabase and in some cases personal commu-
nication with the authors, and required careful considera-
tion and systematization to resolve sequence name ambi-
guities between different laboratories. Antibody sequences
were downloaded from GenBank, and links to the struc-
tures in Protein Data Bank are provided. Standard statis-
tics are applied to tally and analyze neutralization results.
Specifically, antibody associations with viral mutations are
evaluated by Fisher’s exact test, counting the number of
antibody-resistant or antibody-sensitive viruses (above or
below threshold of detection) and the presence or absence
of specific amino acids or N-glycosylation motif in the viral
sequence alignment position (12).
RESULTS
Data retrieval
CATNAP includes neutralization data from published
studies, as well as curated HIV-1 Env alignments corre-
sponding to neutralization panels with carefully standard-
ized virus sequence names. The current collection comprises
172 antibodies and 722 HIV-1 viruses (529 with sequences,
and the remaining 193 viruses were published by compa-
nies, and so the sequences are proprietary) from 49 pub-
lished studies, with more being added frequently.
The input page allows the user to retrieve details about
selected HIV-1 Env sequences and antibodies used in neu-
tralization panels, retrieve available details about the donor
from whom the antibody was isolated, and select viruses
and antibodies both individually and by study, for anal-
ysis (Figure 1). The antibody details option provides, for
the specified antibody(s), links to the corresponding im-
munology database records, notes, references, links to crys-
tal structures in the Protein Data Bank, antibody donor ID
and clonal lineage, data from our Neutralizing Antibody
Contexts and Features Database, and heavy and light chain
antibody variable region mRNA sequences. The virus de-
tails option provides HIV subtype, sampling country, dis-
ease stage information, accession number, neutralization
tier, and Los Alamos Database comments. (In some cases,
the sequence of the virus used in experiments does not ex-
actly correspond to the GenBank sequence. We resolved
these issues to the extent possible via personal communi-
cation with the authors, and the comments associated with
each sequence document whether the GenBank sequence
or the unpublished one from the authors is used.) Impor-
tantly, a sequence name stored in CATNAP corresponds
to the most frequently used name we identified in pub-
lished neutralization studies. In many cases, however, differ-
ent names are used in studies by different groups, and they
frequently do not exactly correspond to the database se-
quence name.Weprovide a list of sequence name aliases and
HIV database name for an easy one-to-one correspondence
between the various short names, database names and ac-
cession numbers, thereby facilitating meta-studies. Finally,
a set of accession numbers of the selected viruses can be au-
tomatically uploaded to the Sequence Search Interface of
our HIV Sequence Database, to obtain information from
many additional sequence database fields. The assay de-
tails option provides a downloadable table of available IC50
and IC80 data for selected viruses and antibodies from each
study. When multiple studies assayed the same antibody–
virus combination, both the original data and the geometric
mean of the repeated data points is shown.
Analysis page
The analysis page superimposes virus data, neutralization
data, and aligned viral sequences on one page. For each
virus-antibody pair, the user can see virus information (tier,
subtype, country, GenBank accession number, sequence
aliases), neutralization values, both per study and the ge-
ometric means, and the virus sequences with highlighted
N-linked glycosylation motifs (Figure 2). Analysis and ad-
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A) Antibody details
B) Virus details
Figure 1. Data retrieval. Examples of antibody and virus retrievable and downloadable details are shown. Green arrows and green text shown on Figures
1–3 represent comments added on the figure, but not present on the web site. (A) Antibody details include antibody structures in the Protein Data Bank;
clickable donor ID from whom the antibody was isolated, which leads to donor information stored in the HIV database; Env positions related to antibody
neutralization; and antibody variable chain sequences. PG9 is the antibody used in the example. The inset on the top of the figure shows an example of
Env positions related to PG9 neutralization; Env positions shown in the inset have mutations that affect PG9 and related bNAb sensitivity. Inset on the
right shows patient details for the donor from whom the antibody was isolated, and provides the link to HIV-1 sequences from that donor. (B) Virus details
include virus name, subtype, country of isolation, patient health and risk status, GenBank accession number, neutralization tier, different names and aliases
used in the literature, and our comments.
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Window can be 
expanded to see
more virus details
Sites of N-linked
glycosylation motifs
Position selected for
analysis is 
highlighted
Breadth and 
potency
Antibody contact
and other important 
virus positions 
Figure 2. Analysis page. Three aligned windows are shown side-by-side. Each window has vertical and horizontal scroll bars, and each window can be
expanded vertically and horizontally by clicking and dragging its right corner. All fields in each window are sortable, and all three windows are sorted
simultaneously. For example, clicking onMAb 10E8 in the center window will sort all 3 windows by 10E8 neutralization scores. The left window lists virus
names included in the analysis as well as neutralization tier, subtype, country, accession number, aliases (expandable data), and the presence of potential
N-linked glycosylation motifs (denoted as NxST). The center window lists antibodies with their color-coded IC50 and/or IC80 neutralization scores. When
multiple studies assayed the same antibody–virus combination, the geometric mean of the data points is shown and marked with an asterisk (*). The
‘Expand’ link shows the data points frommultiple studies used to calculate the geometric means. A mouseover on each individual geometric mean will also
show data-points together with the study references. The right window shows aligned Env sequences, with the HXB2 reference sequence on top. Potential
N-glycosylation sites are highlighted in red. Additional information is provided under the three aligned windows above: breadth of neutralization and
potency of each antibody over the selected group of viruses (potency is calculated two ways: for sensitive viruses that are below neutralization threshold
of detection and for all tested viruses where resistant viruses are set to 100 g/ml.); antibody contact HIV position(s) and a link to the sequence logo of
these positions showing their variability in HIV-1 circulating sequences (see the inset). The option to analyze an individual HIV protein sequence position
is on the bottom of the figure (this position is highlighted on the Env alignment in the right window with a gray vertical line). When a position of interest
is entered, a new ‘AA NxST’ column appears between the virus and antibody windows. This column shows the amino acid found in each sequence at
the position of interest, and the presence of an N-linked glycosylation motif in that position is indicated by ‘+’. N-linked glycosylation motifs are also
highlighted in the alignment in red.
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A)
B)
C)
The entropy at this position has been calculated
based on HIV Sequence database alignments 
Presence or absence of
N-linked glycosylation
motifs
Figure 3. Statistical analysis. (A) Counts of different amino acids at the chosen HXB2 position of ENV are shown, together with the counts of bNAb
PG9 sensitive (detected, that is below threshold of detection) and resistant (undetected, that is above threshold of detection) viruses for each amino acid.
(B) Counts of viruses with and without an N-linked glycosylation motif at the chosen HXB2 position of Env are shown. In (A) and (B), Fisher’s exact
test is based on a contingency table of ‘AA/not AA’ (or ‘NxST/not NxST’) and ‘virus sensitive/not sensitive’. (C) Information from the HIV database
about the position of interest is shown, and includes entropy calculations using HIVDatabase tool Entropy and HIV-1 alignments for M group, and B and
C subtypes, information about functional domains, and antibody features of this position, such as how mutations in this position affect various bNAbs
neutralization sensitivity, signature predictions at this position, mutations affecting antibody binding, etc.
ditional information are provided under the superimposed
data (Figures 2 and 3), and include several options.
 Breadth and potency of each antibody/serum over the
selected group of viruses are assessed, with potency cal-
culated as a geometric mean of neutralization scores of
both antibody-sensitive viruses and all viruses (Figure 2).
 List of Env-antibody contact positions is displayed for
the selected antibodies, with the link to another HIV
database tool, QuickAlign, which aligns these positions
to a large set of sequences from the HIV Sequence
Database and shows sequence logos (amino acid compo-
sitions and frequencies) and summaries of how variable
these positions are in HIV circulating sequences (Fig-
ure 2).
 Antibody signature analysis options highlight a position
of interest in the alignment (Figure 2), and for each se-
quence report the presence or absence of N-glycosylated
motif for in this position (Figure 2), extract further infor-
mation from the HIV databases and perform basic anti-
body signature analysis on this position (Figure 3). The
extracted information includes entropy scores as a mea-
sure of amino acid variability in this position inM group,
B clade and C clade database alignments, protein fea-
tures such as functional domains associated with this po-
sition, antibody contacts and other NAb-associated fea-
tures of this position, such as mutations affecting anti-
body sensitivity, signature predictions, and other features
(Figure 3c). Statistical analysis displays the amino acid
makeup of that position in the alignment (Figure 3a), the
count of viruses with and without N-linked glycosylation
motif (Figure 3b), the count of antibody sensitive and
resistant viruses for each amino acid or N-glycosylation
motif found in this position of the alignment, together
with the corresponding Fisher’s exact test results to de-
tect a potential positive or negative amino acid signature
for the selected antibody (12). In Figure 3b, for example,
an N-glycosylation motif at Env position 160 is enriched
in bNAbPG9-detected viruses (P< 2.2e−16), indicating,
in agreement with published studies (8,31), an associa-
tion of a glycosylation site at position 160 with increased
susceptibility to PG9 neutralization. This analysis should
be interpreted with caution, as the counts are not phylo-
genetically corrected, and significant correlations that are
not directly related to antibody sensitivity may arise as
a consequence of structure in the phylogenetic tree. Still
such associations can be informative, particularly for hy-
pothesis forming or validation of a pre-existing hypoth-
esis. A signature analysis tool that incorporates a phylo-
genetic correction (12) is in progress at the database.
Custom CATNAP
Custom CATNAP allows users to superimpose and ana-
lyze any table of numerical data in conjunction with ge-
netic sequences (Figure 2), and to look for associated ge-
netic signatures (Figure 3). Examples include IC50 neutral-
ization values for monoclonal antibodies, like those used in
the basic CATNAP tool, or ID50 titers for plasma neutral-
ization data, but the tool can be used for any numerical data
(binding kinetic data, functional data) in conjunction with
sequence data. As neutralization data frequently use cut-
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offs, with results below or above a threshold being consid-
ered undetected, for the statistical analysis the user should
choose the type that describes the most potent scores in the
data. For example, IC50 scores for the monoclonal antibod-
ies reflect the concentration needed to achieve 50% neutral-
ization, and so values with a ‘>’ symbol are considered un-
detected. ID50 scores for the plasma antibodies, on the other
hand, reflect the number of dilutions required to reduce the
infectivity by 50%, and the high scores are the most potent,
so the values with a ‘<’ symbol are considered undetected.
Like in basic CATNAP, potential genetic signatures are de-
fined by Fisher’s exact test (12). Users can use their own
alignments, or can use a premade alignment that contains
subsets of Env sequences in the CATNAP tool, including
HIV-1 viral strains commonly used in neutralization pan-
els.
DISCUSSION
Overall, we believe CATNAP is a useful tool for the HIV
research community, particularly good for integrating and
superimposing complete HIV sequence data and broadly
neutralizing antibody data across many studies. It provides
initial signature analysis on the fly, and it can be used to
analyze custom data including genetic sequences in con-
junction with numerical data. We consider CATNAP to
be a foundation for a new neutralizing antibody relational
database, and we plan to expand this resource to con-
tain many more analysis tools and data tables, such as in-
corporating phylogenetic correction in evaluating antibody
signatures in viral sequences (12), listing of germline an-
tibody sequences, antibody variable sequence alignments,
HIV-antibody 3D structure visualization tools, and within-
patient studies with autologous viral and antibody sequence
data.
FUNDING
National Institutes of Health (NIH) [contract
AGRAAI1200700101000HIV/SIV,Database andAnalysis
Unit (B.T.K., H.Y., J.M., B.F., K.Y.) and grant HIVRAD
P01 AI100148 (P.J.B., A.P.W.)]; Bill & Melinda Gates
Foundation [Collaboration for AIDS Vaccine Discovery,
grant 1032144 (B.T.K., H.Y.) and grant 1040753 (P.J.B.,
A.P.W.)]. Funding for open access charge: NIH contract
AGRAAI1200700101000 through Los Alamos National
Laboratory.
Conflict of interest statement.None declared.
REFERENCES
1. Gaschen,B., Taylor,J., Yusim,K., Foley,B., Gao,F., Lang,D.,
Novitsky,V., Haynes,B., Hahn,B.H., Bhattacharya,T. et al. (2002)
Diversity considerations in HIV-1 vaccine selection. Science, 296,
2354–2360.
2. Burton,D.R., Poignard,P., Stanfield,R.L. and Wilson,I.A. (2012)
Broadly neutralizing antibodies present new prospects to counter
highly antigenically diverse viruses. Science, 337, 183–186.
3. Scheid,J.F., Mouquet,H., Ueberheide,B., Diskin,R., Klein,F.,
Oliveira,T.Y., Pietzsch,J., Fenyo,D., Abadir,A., Velinzon,K. et al.
(2011) Sequence and structural convergence of broad and potent HIV
antibodies that mimic CD4 binding. Science, 333, 1633–1637.
4. Wu,X., Zhou,T., Zhu,J., Zhang,B., Georgiev,I., Wang,C., Chen,X.,
Longo,N.S., Louder,M., McKee,K. et al. (2011) Focused evolution of
HIV-1 neutralizing antibodies revealed by structures and deep
sequencing. Science, 333, 1593–1602.
5. deCamp,A., Hraber,P., Bailer,R.T., Seaman,M.S., Ochsenbauer,C.,
Kappes,J., Gottardo,R., Edlefsen,P., Self,S., Tang,H. et al. (2014)
Global panel of HIV-1 Env reference strains for standardized
assessments of vaccine-elicited neutralizing antibodies. J. Virol., 88,
2489–2507.
6. Seaman,M.S., Janes,H., Hawkins,N., Grandpre,L.E., Devoy,C.,
Giri,A., Coffey,R.T., Harris,L., Wood,B., Daniels,M.G. et al. (2010)
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses
for assessment of neutralizing antibodies. J. Virol., 84, 1439–1452.
7. Montefiori,D.C. (2005) Evaluating neutralizing antibodies against
HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc.
Immunol., Chapter 12, Unit 12.11.
8. West,A.P. Jr, Scharf,L., Horwitz,J., Klein,F., Nussenzweig,M.C. and
Bjorkman,P.J. (2013) Computational analysis of anti-HIV-1 antibody
neutralization panel data to identify potential functional epitope
residues. Proc. Natl .Acad. Sci. U.S.A., 110, 10598–10603.
9. Eroshkin,A.M., LeBlanc,A., Weekes,D., Post,K., Li,Z., Rajput,A.,
Butera,S.T., Burton,D.R. and Godzik,A. (2014) bNAber: database of
broadly neutralizing HIV antibodies. Nucleic Acids Res., 42,
D1133–D1139.
10. Chuang,G.Y., Acharya,P., Schmidt,S.D., Yang,Y., Louder,M.K.,
Zhou,T., Kwon,Y.D., Pancera,M., Bailer,R.T., Doria-Rose,N.A. et al.
(2013) Residue-level prediction of HIV-1 antibody epitopes based on
neutralization of diverse viral strains. J. Virol., 87, 10047–10058.
11. Chuang,G.Y., Liou,D., Kwong,P.D. and Georgiev,I.S. (2014) NEP:
web server for epitope prediction based on antibody neutralization of
viral strains with diverse sequences. Nucleic Acids Res., 42,
W64–W71.
12. Gnanakaran,S., Daniels,M.G., Bhattacharya,T., Lapedes,A.S.,
Sethi,A., Li,M., Tang,H., Greene,K., Gao,H., Haynes,B.F. et al.
(2010) Genetic signatures in the envelope glycoproteins of HIV-1 that
associate with broadly neutralizing antibodies. PLoS Comput. Biol.,
6, e1000955.
13. Kepler,T.B. (2013) Reconstructing a B-cell clonal lineage. I. Statistical
inference of unobserved ancestors. F1000Res, 2, 103.
14. Ye,J., Ma,N., Madden,T.L. and Ostell,J.M. (2013) IgBLAST: an
immunoglobulin variable domain sequence analysis tool. Nucleic
Acids Res., 41, W34–W40.
15. Giudicelli,V., Brochet,X. and Lefranc,M.P. (2011) IMGT/V-QUEST:
IMGT standardized analysis of the immunoglobulin (IG) and T cell
receptor (TR) nucleotide sequences. Cold Spring Harb. Protoc.,
695–715.
16. Brochet,X., Lefranc,M.P. and Giudicelli,V. (2008) IMGT/V-QUEST:
the highly customized and integrated system for IG and TR
standardized V-J and V-D-J sequence analysis. Nucleic Acids Res., 36,
W503–W508.
17. Gaeta,B.A., Malming,H.R., Jackson,K.J., Bain,M.E., Wilson,P. and
Collins,A.M. (2007) iHMMune-align: hidden Markov model-based
alignment and identification of germline genes in rearranged
immunoglobulin gene sequences. Bioinformatics, 23, 1580–1587.
18. Souto-Carneiro,M.M., Longo,N.S., Russ,D.E., Sun,H.W. and
Lipsky,P.E. (2004) Characterization of the human Ig heavy chain
antigen binding complementarity determining region 3 using a newly
developed software algorithm, JOINSOLVER. J. Immunol., 172,
6790–6802.
19. Liao,H.X., Lynch,R., Zhou,T., Gao,F., Alam,S.M., Boyd,S.D.,
Fire,A.Z., Roskin,K.M., Schramm,C.A., Zhang,Z. et al. (2013)
Co-evolution of a broadly neutralizing HIV-1 antibody and founder
virus. Nature, 496, 469–476.
20. Diskin,R., Scheid,J.F., Marcovecchio,P.M., West,A.P. Jr, Klein,F.,
Gao,H., Gnanapragasam,P.N., Abadir,A., Seaman,M.S.,
Nussenzweig,M.C. et al. (2011) Increasing the potency and breadth
of an HIV antibody by using structure-based rational design. Science,
334, 1289–1293.
21. Pejchal,R., Doores,K.J., Walker,L.M., Khayat,R., Huang,P.S.,
Wang,S.K., Stanfield,R.L., Julien,J.P., Ramos,A., Crispin,M. et al.
(2011) A potent and broad neutralizing antibody recognizes and
penetrates the HIV glycan shield. Science, 334, 1097–1103.
22. Falkowska,E., Ramos,A., Feng,Y., Zhou,T., Moquin,S.,
Walker,L.M., Wu,X., Seaman,M.S., Wrin,T., Kwong,P.D. et al.
 at California Institute of Technology on Septem
ber 10, 2015
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research, 2015, Vol. 43, Web Server issue W219
(2012) PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad
and potent in neutralization but does not induce conformational
changes characteristic of CD4. J. Virol., 86, 4394–4403.
23. Blattner,C., Lee,J.H., Sliepen,K., Derking,R., Falkowska,E., de la
Pena,A.T., Cupo,A., Julien,J.P., van Gils,M., Lee,P.S. et al. (2014)
Structural delineation of a quaternary, cleavage-dependent epitope at
the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity, 40,
669–680.
24. Scharf,L., Scheid,J.F., Lee,J.H., West,A.P. Jr, Chen,C., Gao,H.,
Gnanapragasam,P.N., Mares,R., Seaman,M.S., Ward,A.B. et al.
(2014) Antibody 8ANC195 reveals a site of broad vulnerability on the
HIV-1 envelope spike. Cell Rep., 7, 785–795.
25. McLellan,J.S., Pancera,M., Carrico,C., Gorman,J., Julien,J.P.,
Khayat,R., Louder,R., Pejchal,R., Sastry,M., Dai,K. et al. (2011)
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing
antibody PG9. Nature, 480, 336–343.
26. Zhou,T., Georgiev,I., Wu,X., Yang,Z.Y., Dai,K., Finzi,A.,
Kwon,Y.D., Scheid,J.F., Shi,W., Xu,L. et al. (2010) Structural basis
for broad and potent neutralization of HIV-1 by antibody VRC01.
Science, 329, 811–817.
27. Zhou,T., Xu,L., Dey,B., Hessell,A.J., Van Ryk,D., Xiang,S.H.,
Yang,X., Zhang,M.Y., Zwick,M.B., Arthos,J. et al. (2007) Structural
definition of a conserved neutralization epitope on HIV-1 gp120.
Nature, 445, 732–737.
28. Kwong,P.D., Wyatt,R., Robinson,J., Sweet,R.W., Sodroski,J. and
Hendrickson,W.A. (1998) Structure of an HIV gp120 envelope
glycoprotein in complex with the CD4 receptor and a neutralizing
human antibody. Nature, 393, 648–659.
29. O’Rourke,S.M., Schweighardt,B., Phung,P., Mesa,K.A.,
Vollrath,A.L., Tatsuno,G.P., To,B., Sinangil,F., Limoli,K., Wrin,T.
et al. (2012) Sequences in glycoprotein gp41, the CD4 binding site,
and the V2 domain regulate sensitivity and resistance of HIV-1 to
broadly neutralizing antibodies. J. Virol., 86, 12105–12114.
30. Postler,T.S. and Desrosiers,R.C. (2013) The tale of the long tail: the
cytoplasmic domain of HIV-1 gp41. J. Virol., 87, 2–15.
31. Doria-Rose,N.A., Georgiev,I., O’Dell,S., Chuang,G.Y., Staupe,R.P.,
McLellan,J.S., Gorman,J., Pancera,M., Bonsignori,M., Haynes,B.F.
et al. (2012) A short segment of the HIV-1 gp120 V1/V2 region is a
major determinant of resistance to V1/V2 neutralizing antibodies. J.
Virol., 86, 8319–8323.
 at California Institute of Technology on Septem
ber 10, 2015
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
